Dysthymic disorder
disease diseaseOn this page
Also known as dysthymia
Summary
Dysthymic disorder (MONDO:0001442) is a disease with 1 GWAS associations across 6 studies and 54 clinical trials. Top therapeutic interventions include bupropion, escitalopram, and desvenlafaxine. A subtype of mood disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- GWAS associations: 1
- Clinical trials: 54
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | dysthymic disorder |
| Mondo ID | MONDO:0001442 |
| EFO | EFO:0008623 |
| MeSH | D019263 |
| DOID | DOID:12139 |
| ICD-10-CM | F34.1 |
| ICD-11 | 810797047 |
| NCIT | C34562 |
| SNOMED CT | 78667006 |
| UMLS | C0013415 |
| MedGen | 8517 |
| Is cancer (heuristic) | no |
Also known as: dysthymia
Data availability: 1 GWAS association (6 studies).
Disease family
This is a subtype of mood disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › mental disorder › mood disorder › dysthymic disorder
Related subtypes (4): atypical depressive disorder, depressive disorder, cyclothymic disorder, bipolar disorder
Genetics & variants
GWAS landscape
1 GWAS associations across 6 studies. Top hits map to 0 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs5956639 | 1e-06 | TCERG1P1 - KLHL13 | ? |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90481781 | Verma A | 2024 | 32,376 | 400,491 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90481780 | Verma A | 2024 | 8,837 | 107,075 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90481778 | Verma A | 2024 | 3,972 | 53,371 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90652225 | Liu TY | 2025 | 3,169 | 143,233 | Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population. |
| GCST90481779 | Verma A | 2024 | 230 | 6,415 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90435869 | Zhou W | 2018 | 53 | 365,476 | Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 1 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 1 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 0 |
| unknown | 0 |
Functional consequences
| Consequence | Count |
|---|---|
| intergenic_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs5956639 | X | 117419420 | A>G,T | 0.05 | intergenic_variant | TCERG1P1 - KLHL13 | 1e-06 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated or in trials for this disease
No drug has an approved disease-direct ChEMBL indication for this disease.
1 drug in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.
| Drug | Highest phase |
|---|---|
| OMEGA-3-ACID ETHYL ESTERS | Phase 2 |
Clinical trials & evidence
Clinical trials
Clinical trials: 54.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 27 |
| PHASE4 | 16 |
| PHASE2 | 5 |
| PHASE1/PHASE2 | 3 |
| PHASE2/PHASE3 | 1 |
| PHASE3 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00220701 | PHASE4 | COMPLETED | Escitalopram in the Treatment of Dysthymic Disorder, Double Blind |
| NCT00225251 | PHASE4 | COMPLETED | Wellbutrin XL for Dysthymic Disorder |
| NCT00234312 | PHASE4 | COMPLETED | Medications for the Treatment of Dysthymic Disorder and Double Depression |
| NCT00260390 | PHASE4 | UNKNOWN | Testosterone Replacement in Middle-Aged Hypogonadal Men With Dysthymia: Parallel Group, Double Blind Randomized Trial |
| NCT00296712 | PHASE4 | COMPLETED | Are Two Antidepressants a Good Initial Treatment for Depression? |
| NCT00296777 | PHASE4 | COMPLETED | Treatment of Depression Following Multiple Brain Tests |
| NCT00360724 | PHASE4 | COMPLETED | Duloxetine for Chronic Depression: a Double-blind Study |
| NCT00404755 | PHASE4 | COMPLETED | Dichotic Listening as a Predictor of Medication Response in Depression |
| NCT00518986 | PHASE4 | COMPLETED | Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression |
| NCT00592384 | PHASE4 | COMPLETED | Project to Improve Symptoms and Mood in People With Spinal Cord Injury |
| NCT01537068 | PHASE4 | COMPLETED | Desvenlafaxine vs. Placebo Treatment of Chronic Depression |
| NCT01852383 | PHASE4 | COMPLETED | Duloxetine Treatment in Elderly With Dysthymia |
| NCT01942187 | PHASE4 | WITHDRAWN | A Comparison of Medication Augmentation and PST in the Treatment of Depression in Older Adults |
| NCT01973283 | PHASE4 | COMPLETED | Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults |
| NCT02744391 | PHASE4 | COMPLETED | A Study of L-DOPA for Depression and Slowing in Older Adults |
| NCT03761030 | PHASE4 | TERMINATED | L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults |
| NCT01443715 | PHASE2/PHASE3 | COMPLETED | A Stepped Care Model of Adolescent Depression Treatment in Primary Care |
| NCT01447602 | PHASE3 | COMPLETED | A Clinical Trial of IPT-A to Prevent Suicide in Depressed Adolescents With Suicidal Behavior |
| NCT00073359 | PHASE1/PHASE2 | COMPLETED | Effects of Therapist Behavior on the Treatment of Depressed Adolescents |
| NCT00238758 | PHASE2 | UNKNOWN | A Study of Omega-3 as a Treatment for Major Depression |
| NCT00296725 | PHASE1/PHASE2 | COMPLETED | Dichotic Listening as a Predictor of Medication Response in Depression |
| NCT00883519 | PHASE1/PHASE2 | COMPLETED | The Efficacy of Parent Involvement in the Treatment of Adolescent Depression |
| NCT01189812 | PHASE2 | COMPLETED | Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms |
| NCT02458690 | PHASE2 | COMPLETED | eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients |
| NCT04121091 | PHASE2 | COMPLETED | Pramipexole to Target Anhedonic Depression |
| NCT04437485 | PHASE2 | COMPLETED | eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk |
| NCT00619411 | PHASE1 | COMPLETED | Interpersonal Psychotherapy for Depressed Adolescents and Parents |
| NCT04664374 | Not specified | ACTIVE_NOT_RECRUITING | Characterizing MyMood Patterns of Use |
| NCT05118594 | Not specified | NOT_YET_RECRUITING | Testing a Precision Psychotherapy System for Low-income Patients |
| NCT06724666 | Not specified | RECRUITING | Transdiagnostic Internet-delivered Intervention for Adolescents With Anxiety and Depression |
| NCT00096642 | Not specified | COMPLETED | Cognitive Behavioral Therapy for Early-Onset Depression |
| NCT00482482 | Not specified | COMPLETED | Yoga in Unipolar and Bipolar Disorders |
| NCT00565110 | Not specified | COMPLETED | Treating Depression Among Low-Income Patients With Cancer |
| NCT00579267 | Not specified | COMPLETED | Reliability and Validity of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-KID) |
| NCT00688818 | Not specified | COMPLETED | Quetiapine in Co-Morbid Depressive and Anxiety Disorders |
| NCT01385709 | Not specified | COMPLETED | The Influence of the Menstrual Cycle on Lithium and Sertraline Blood Levels |
| NCT01473615 | Not specified | UNKNOWN | Mindfulness Based Cognitive Therapy for Chronic Pain and Comorbid Unipolar Depression |
| NCT01528748 | Not specified | COMPLETED | Clinical Trial of CBASP for Individuals With Co-occurring Chronic Depression and Alcohol Dependence |
| NCT01542957 | Not specified | COMPLETED | Cognitive Therapy for Unipolar Depression: Efficacy of a Dilemma-Focused Intervention |
| NCT01561105 | Not specified | COMPLETED | Improving Depression Care for Elders: Coordinating Center |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| BUPROPION | 4 | 12 |
| ESCITALOPRAM | 4 | 11 |
| DESVENLAFAXINE | 4 | 6 |
| IMIPRAMINE | 4 | 6 |
| CITALOPRAM | 4 | 3 |
| FLUOXETINE | 4 | 3 |
| DULOXETINE | 4 | 2 |
| LEVODOPA | 4 | 2 |
| ARIPIPRAZOLE | 4 | 1 |
| ARMODAFINIL | 4 | 1 |
| LITHIUM CARBONATE | 4 | 1 |
| PRAMIPEXOLE | 4 | 1 |
| SERTRALINE | 4 | 1 |
| DEXPRAMIPEXOLE | 3 | 1 |
| (R)-DULOXETINE | 0 | 2 |
| CHEMBL1788361 | 0 | 1 |
| CHEMBL351042 | 0 | 1 |
| CHEMBL498563 | 0 | 1 |
| CHEMBL1201343 | 0 | 1 |